0 Commentarii
0 Distribuiri
482 Views
0 previzualizare
Căutare
Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni
-
Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
-
Injectable Targeted Therapy Market Size, Share, Trends & Forecast 2033According to the latest report published by Data Bridge Market Research, the Injectable Targeted Therapy Market CAGR Value Injectable Targeted Therapy Market survey report is intended to help the readers develop a practical and intelligent approach to market dynamics and exploit opportunities, therefore. The market report also contains the drivers and restraints for the...0 Commentarii 0 Distribuiri 38 Views 0 previzualizare
-
HDAC Inhibitor Market Segmentation Analysis by Indication and End UserThe global HDAC inhibitor market is gaining significant momentum as the healthcare industry continues to advance targeted therapies for cancer and other complex diseases. Histone deacetylase (HDAC) inhibitors are a class of compounds that regulate gene expression by altering chromatin structure, making them valuable in the treatment of various malignancies and epigenetic disorders. The...0 Commentarii 0 Distribuiri 2K Views 0 previzualizare
-
Regional Growth Prospects for the Ovarian Cancer Drugs MarketThe Ovarian Cancer Drugs Market is evolving as the need for effective cancer treatments increases worldwide. Valued at USD 3.4 billion in 2022, the Ovarian Cancer Drugs Market is projected to reach USD 5.7 billion by 2030, expanding at a CAGR of 6.6% from 2023 to 2030. Growing ovarian cancer incidence, advances in targeted medicines, and the development of innovative therapies are supporting...0 Commentarii 0 Distribuiri 1K Views 0 previzualizare
-
United States ADC for Solid Tumors Market Growing at 8.9% CAGR Through 2034The United States Antibody‑Drug Conjugate (ADC) for Solid Tumors market size was valued at approximately USD 0.55 billion in 2025. The market is projected to grow from approximately USD 0.58 billion in 2026 to around USD 1.04 billion by 2034, exhibiting a CAGR of about 8.9% during the forecast period. Antibody‑Drug Conjugates are targeted therapeutics that combine a monoclonal antibody that...0 Commentarii 0 Distribuiri 2K Views 0 previzualizare